Back to top
more

Kura Oncology (KURA)

(Real Time Quote from BATS)

$20.52 USD

20.52
184,661

+0.90 (4.59%)

Updated May 1, 2024 03:03 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations

by Zacks Equity Research

Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.

What Makes Kura Oncology (KURA) a New Buy Stock

by Zacks Equity Research

Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Kura Oncology (KURA) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Kura Oncology (KURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Wall Street Analysts Believe Kura Oncology (KURA) Could Rally 111%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at an 110.5% upside potential for Kura Oncology (KURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Is Kura Oncology (KURA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Kura Oncology (KURA) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.

Wall Street Analysts Think Kura Oncology (KURA) Could Surge 116%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 115.6% in Kura Oncology (KURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Kura Oncology (KURA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.

Kura Oncology (KURA) Looks Good: Stock Adds 6.8% in Session

by Zacks Equity Research

Kura Oncology (KURA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Kura Oncology, Inc. (KURA) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Kura Oncology, Inc. (KURA).

Company News For Jun 17, 2019

by Zacks Equity Research

Companies In The News Are: FB,BXG,ARQL,KURA

Zacks.com featured highlights include Build-A-Bear Workshop, Kura Oncology, Norsk Hydro, Schnitzer Steel Industries and SYNNEX

by Zacks Equity Research

Zacks.com featured highlights include Build-A-Bear Workshop, Kura Oncology, Norsk Hydro, Schnitzer Steel Industries and SYNNEX

    5 Stocks in Limelight on New Analyst Coverage

    by Zacks Equity Research

    Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

      Can Kura Oncology (KURA) Run Higher on Strong Earnings Estimate Revisions?

      by Zacks Equity Research

      Kura Oncology (KURA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

        3 Reasons Momentum Stock Investors Will Love Kura Oncology (KURA)

        by Zacks Equity Research

        Kura Oncology (KURA) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.

          Kura Oncology (KURA) Catches Eye: Stock Jumps 6.8%

          by Zacks Equity Research

          Kura Oncology (KURA) saw its shares rise almost 7% in the last trading session.

            Kura Oncology Starts Dosing Patients in Phase II CMML Study

            by Zacks Equity Research

            Kura Oncology (KURA) dosed the first patient in a phase II study on tipifarnib for the treatment of chronic myelomonocytic leukemia.